Xencor (XNCR) Revenue & Revenue Breakdown
Xencor Revenue Highlights
Latest Revenue (Y)
$168.34M
Latest Revenue (Q)
$16.96M
Main Segment (Y)
Milestone
Main Geography (Y)
U
Xencor Revenue by Period
Xencor Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 2.28% |
2022-12-31 | - | -40.18% |
2021-12-31 | - | 124.23% |
2020-12-31 | - | -21.70% |
2019-12-31 | - | 285.93% |
2018-12-31 | - | 13.70% |
2017-12-31 | - | -59.20% |
2016-12-31 | - | 215.25% |
2015-12-31 | - | 191.62% |
2014-12-31 | - | -6.41% |
2013-12-31 | - | 6.80% |
2012-12-31 | - | 39.06% |
2011-12-31 | - | - |
Xencor Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | - | 32.45% |
2024-03-31 | - | -71.35% |
2023-12-31 | - | -24.47% |
2023-09-30 | - | 29.97% |
2023-06-30 | - | 140.07% |
2023-03-31 | - | -12.25% |
2022-12-31 | - | -20.84% |
2022-09-30 | - | -9.53% |
2022-06-30 | - | -64.71% |
2022-03-31 | - | -44.49% |
2021-12-31 | - | 682.48% |
2021-09-30 | - | -70.82% |
2021-06-30 | - | 98.58% |
2021-03-31 | - | -18.85% |
2020-12-31 | - | 18.35% |
2020-09-30 | - | 170.20% |
2020-06-30 | - | -59.58% |
2020-03-31 | - | 821.08% |
2019-12-31 | - | -83.84% |
2019-09-30 | - | 11.68% |
2019-06-30 | - | -82.59% |
2019-03-31 | - | 868.00% |
2018-12-31 | - | -60.18% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | -100.00% |
2017-12-31 | - | 54.32% |
2017-09-30 | - | -46.85% |
2017-06-30 | - | 207.37% |
2017-03-31 | - | -32.61% |
2016-12-31 | - | -17.66% |
2016-09-30 | - | -88.15% |
2016-06-30 | - | 810.19% |
2016-03-31 | - | -66.66% |
2015-12-31 | - | 521.01% |
2015-09-30 | - | 245.46% |
2015-06-30 | - | -31.99% |
2015-03-31 | - | -73.68% |
2014-12-31 | - | 567.92% |
2014-09-30 | - | 2.91% |
2014-06-30 | - | -62.27% |
2014-03-31 | - | 25.23% |
2013-12-31 | - | -44.85% |
2013-09-30 | - | -19.36% |
2013-06-30 | - | 191.52% |
2013-03-31 | - | -44.54% |
2012-12-31 | - | 53.87% |
2012-09-30 | - | - |
Xencor Revenue Breakdown
Xencor Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
---|---|---|---|---|---|
License | - | - | - | - | - |
Royalty | - | - | - | - | - |
Research collaboration | - | - | - | - | - |
Milestone | - | - | - | - | - |
Royalties | - | - | - | - | - |
Licensing | - | - | - | - | - |
Collaboration | - | - | - | - | - |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non-cash Royalty | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Royalty | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Milestone | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Research collaboration | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Royalties | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Collaboration | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
License | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Latest
Xencor Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 20 | Dec 19 | Dec 18 |
---|---|---|---|
Non United States | - | - | - |
U | - | - | - |
Latest
Xencor Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
XNCR | Xencor | - | - |
STRO | Sutro Biopharma | - | - |
ACLX | Arcellx | - | - |
PTGX | Protagonist Therapeutics | - | - |
MRUS | Merus | - | - |
IDYA | IDEAYA Biosciences | - | - |
ANAB | AnaptysBio | - | - |
MGTX | MeiraGTx | - | - |
FIXX | Q32 Bio | - | - |
VRDN | Viridian Therapeutics | - | - |
KROS | Keros Therapeutics | - | - |
PCVX | Vaxcyte | - | - |
NUVL | Nuvalent | - | - |
DICE | DICE Therapeutics | - | - |
CERE | Cerevel Therapeutics | - | - |
REPL | Replimune Group | - | - |
KURA | Kura Oncology | - | - |
ERAS | Erasca | - | - |
SNDX | Syndax Pharmaceuticals | - | - |
MLYS | Mineralys Therapeutics | - | - |
LRMR | Larimar Therapeutics | - | - |
GLUE | Monte Rosa Therapeutics | - | - |
EWTX | Edgewise Therapeutics | - | - |